Five Prime Therapeutics Inc. (NASDAQ:FPRX) fell 3.7% on Wednesday . The stock traded as low as $44.00 and last traded at $44.56, with a volume of 163,099 shares traded. The stock had previously closed at $46.25.

Several brokerages have weighed in on FPRX. Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a research note on Sunday, May 8th. Jefferies Group reissued a “buy” rating on shares of Five Prime Therapeutics in a research note on Sunday, May 8th. Leerink Swann reissued an “outperform” rating and set a $58.00 price objective (up from $45.00) on shares of Five Prime Therapeutics in a research note on Monday, August 8th. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $48.00 price objective on shares of Five Prime Therapeutics in a research note on Thursday, May 19th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $52.33.

The company’s 50-day moving average price is $47.12 and its 200-day moving average price is $42.37. The firm has a market cap of $1.18 billion and a PE ratio of 4.95.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.07. The firm had revenue of $9.23 million for the quarter, compared to analysts’ expectations of $6.38 million. The company’s revenue was up 46.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.45) earnings per share. Equities analysts forecast that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current year.

In related news, Director Peder Jensen sold 12,195 shares of the firm’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total value of $603,652.50. Following the transaction, the director now directly owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director William R. Ringo sold 500 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $50.77, for a total transaction of $25,385.00. Following the completion of the transaction, the director now directly owns 500 shares in the company, valued at $25,385. The disclosure for this sale can be found here.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.